Plain-English translation of NCT07296315 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing MH002, a new type of medicine that contains live bacteria designed to help restore a healthy gut in people with ulcerative colitis. The study will test two different doses of this medication and compare them to a placebo (a dummy treatment with no active ingredient) to see which dose works best and is safest. A smaller earlier study showed promising results, so researchers now want to confirm these findings in a larger group of patients.
Many people with ulcerative colitis don't respond well enough to the standard first-line treatment (5-aminosalicylic acid). This trial exists to see whether this medication—which restores beneficial bacteria to the gut—could be a better option for patients whose symptoms aren't adequately controlled or who can't tolerate current treatments.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to receive either the low dose of the medication, the high dose, or a placebo—neither you nor the study team will know which you're getting until the study ends. You'll visit the clinic regularly for check-ups, blood tests, and possibly colonoscopies to see how your gut is healing. The study will track your symptoms and side effects over several weeks to months to determine whether the treatment works and which dose is best.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
United States